Genomics in acute lymphoblastic leukaemia: insights and treatment implications

Nature Reviews. Clinical Oncology
Kathryn G Roberts, Charles G Mullighan

Abstract

Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important cause of morbidity from haematological malignancies in adults. In the past several years, we have witnessed major advances in the understanding of the genetic basis of ALL. Genome-wide profiling studies, including microarray analysis and genome sequencing, have helped identify multiple key cellular pathways that are frequently mutated in ALL such as lymphoid development, tumour suppression, cytokine receptors, kinase and Ras signalling, and chromatin remodeling. These studies have characterized new subtypes of ALL, notably Philadelphia chromosome-like ALL, which is a high-risk subtype characterized by a diverse range of alterations that activate cytokine receptors or tyrosine kinases amenable to inhibition with approved tyrosine kinase inhibitors. Genomic profiling has also enabled the identification of inherited genetic variants of ALL that influence the risk of leukaemia development, and characterization of the relationship between genetic variants, clonal heterogeneity and the risk of relapse. Many of these findings are of direct clinical relevance and ongoing studies implementing clinical sequencing in leukaemia diagnosis and management h...Continue Reading

References

Mar 7, 2002·Journal of Pediatric Hematology/oncology·J GumpS P Hunger
Aug 28, 2002·Reviews in Clinical and Experimental Hematology·Christine J Harrison, Letizia Foroni
May 19, 2004·British Journal of Haematology·Christine J HarrisonUNKNOWN Childhood and Adult Leukaemia Working Parties
Oct 29, 2005·Science·Scott A TomlinsArul M Chinnaiyan
Nov 11, 2006·Blood·Anthony V MoormanUNKNOWN UK Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Childhood Leukaemia Working Party (CLWP)
Nov 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Teresa PalomeroAdolfo A Ferrando
Mar 9, 2007·Nature·Charles G MullighanJames R Downing
May 3, 2007·Blood·James B NachmanGritta E Janka-Schaub
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciUNKNOWN Cancer and Leukemia Group B Study
Jul 25, 2007·The Journal of Experimental Medicine·Jennifer O'NeilA Thomas Look
Sep 18, 2007·Nature Medicine·Teresa PalomeroAdolfo A Ferrando
Apr 15, 2008·Nature·Charles G MullighanJames R Downing
Apr 19, 2008·Nature Reviews. Immunology·Iannis AifantisSilvia Buonamici
Oct 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Qian AnJon C Strefford
Nov 14, 2008·British Journal of Haematology·Christine J Harrison
Nov 29, 2008·Science·Charles G MullighanJames R Downing
Jan 6, 2009·British Journal of Haematology·Amos GaikwadKaren R Rabin
Jan 9, 2009·The New England Journal of Medicine·Charles G MullighanUNKNOWN Children's Oncology Group
Jan 17, 2009·The Lancet Oncology·Elaine Coustan-SmithDario Campana
Jan 30, 2009·JAMA : the Journal of the American Medical Association·Jun J YangMary V Relling
May 6, 2009·Genes, Chromosomes & Cancer·Kajsa Paulsson, Bertil Johansson
May 9, 2009·International Journal of Oncology·Norihiko KawamataH Phillip Koeffler
May 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Charles G MullighanCheryl L Willman
Jun 6, 2009·Blood·Valeria ToselloAdolfo A Ferrando
Jun 26, 2009·The New England Journal of Medicine·Ching-Hon PuiMary V Relling
Aug 18, 2009·Nature Genetics·Lisa R TreviñoMary V Relling

❮ Previous
Next ❯

Citations

Dec 25, 2015·Diabetologia·Susanne M CabreraMartin J Hessner
Apr 12, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Hara Prasad Pati, Prashant Sharma
Apr 7, 2016·Cancer Cell·Timothy N PhoenixRichard J Gilbertson
Jul 3, 2015·Molecular Cytogenetics·Moneeb A K OthmanThomas Liehr
Aug 1, 2015·Genome Medicine·Stephen F KingsmoreErin Guest
Mar 19, 2016·Cancer Science·Takafumi Yokota, Yuzuru Kanakura
Jul 28, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Andra-Sorina TatarSimion Astilean
Nov 7, 2016·Mayo Clinic Proceedings·Shilpa PaulElias J Jabbour
May 31, 2017·British Journal of Cancer·Maribel Forero-CastroJesús-María Hernández-Rivas
Dec 4, 2016·Hematology·Thai Hoa Tran, Mignon L Loh
Oct 4, 2016·Therapeutic Advances in Hematology·Nikolaos Papadantonakis, Anjali S Advani
Feb 13, 2018·Proceedings of the National Academy of Sciences of the United States of America·Fabian MüllerIra Pastan
Oct 7, 2017·Nature Medicine·Adolfo A Ferrando, Carlos López-Otín
Apr 27, 2019·JAMA Network Open·Fida KhaterDaniel Sinnett
Jun 23, 2019·International Journal of Molecular Sciences·Elena FolliniGiovanni Roti
Aug 14, 2019·Wiley Interdisciplinary Reviews. RNA·Carla NecklesNatasha J Caplen
Apr 28, 2018·Clinical Medicine : Journal of the Royal College of Physicians of London·Niels Asger Jakobsen, Paresh Vyas
Dec 8, 2015·Hematology·Sabina Chiaretti, Robin Foà
Jun 4, 2019·Frontiers in Cell and Developmental Biology·Anthony K N Chan, Chun-Wei Chen
Oct 24, 2019·Archives of Pathology & Laboratory Medicine·Sarika Jain, Anu Abraham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.